SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2025-10-24
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the
safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy
volunteers and multiple doses of SG301 SC injection in participants with systemic lupus
erythematosus (SLE).